Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arvinas to $72 from $88 and keeps a Buy rating on the shares. The bear case emerging post-VERITAC is that ARV-471 will not find a home in the ESR1 wild-type population, Nochomovitz tells investors in a research note. The anlayst believes ARV-471 will find predominant share in ESR1m and therefore stratified his model for ESR1 to reflect weaker penetration/duration in ESR1wt.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Analysts Say These 2 ‘Strong Buy’ Stocks Are Their Top Picks for 2023
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
- Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update